empty

MHRA reclassifies Nuromol from P to GSL

The Medicines and Healthcare products Regulatory Agency has reclassified Nuromol as a general sales list medicine following a public consultation.

The regulator said it decided to make the painkiller a GSL medicine so patients can access it more easily. 

“This reclassification to general sales list will help people to manage their pain where paracetamol or ibuprofen alone have not provided adequate pain relief,” said Dr Sarah Branch, director of vigilance and risk management of medicines at the MHRA.

“Wider availability of medicinal products and improved patient access and choice remain high on the health agenda. The MHRA is committed to improving access to medicinal products for self-care where it is safe to do so.”

Nuromol contains 200mg of ibuprofen and 500mg of paracetamol per tablet and is used to relieve pain associated with a number of conditions such as migraine, backache, period pain, dental pain and rheumatic and muscular pain.



This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.